Filter the drugs by their COVID-19 status ,phase of research and how they help

COVID-19 is a respiratory disease caused by the SARS-CoV-2 virus. Browse the database of potential drugs for COVID-19 treatment compiled by the AIM tool.
Substance COVID-19 status Phase of research How it helps  Latest publication
VHH U
Potential treatment - pre-clinical evidence Experimental Antiviral Feb/12/2021
VHH E
Potential treatment - pre-clinical evidence Experimental Antiviral Feb/12/2021
NBP11
Potential treatment - pre-clinical evidence Experimental Antiviral Feb/14/2021
Cilgavimab
Emergency use authorization Experimental Antiviral Jun/18/2022
1-{3-[2-Hydroxy-3-(4-methylpiperidino)propoxy]phenoxy}-3-(4-methylpiperidino)-2-propanol
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/23/2021
NBP10
Potential treatment - pre-clinical evidence Experimental Antiviral Feb/14/2021
VH-Fc ab8
Potential treatment - pre-clinical evidence Experimental Antiviral Apr/29/2021
2-{3-[3-Chloro-5-(cyclopropylmethoxy)phenyl]-2-oxo[2H-[1,3'-bipyridine]]-5-yl}benzonitrile
Potential treatment - pre-clinical evidence Experimental Antiviral Feb/22/2021
ABP18
Potential treatment - pre-clinical evidence Experimental Antiviral Feb/14/2021
S-8510
Potential treatment - theoretical effect Experimental Antiviral Feb/08/2021
N-[(2S)-1-[[(3S)-1-(benzenesulfonyl)-5-phenylpentan-3-yl]amino]-1-oxo-3-phenylpropan-2-yl]-4-methylpiperazine-1-carboxamide
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/31/2021
(2s,3r)-2-(3,4-Dihydroxyphenyl)-3,7-dihydroxy-2,3-dihydro-4h-chromen-4-one
Potential treatment - theoretical effect Experimental Antiviral Feb/08/2021
mAb 58
Potential treatment - pre-clinical evidence Experimental Antiviral Jan/04/2022
PF-00835231
Potential treatment - pre-clinical evidence Experimental Antiviral Jan/26/2022
COV2-2489
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/16/2021
Nb11‐59
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/04/2021
COV2-2676
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/16/2021
12f
Potential treatment - pre-clinical evidence Experimental Antiviral Feb/08/2021
SinaCurcumin®
Potential treatment - clinical evidence Experimental Antiviral Mar/28/2021
Nirmatrelvir
Emergency use authorization Experimental Antiviral Jun/23/2022